Hoffmann-la Roche Inc.

Institut De Cardiologie De Montreal

Montreal Heart Institute

Quatro Scientific, Inc.

9494-1861 Québec Inc.

F. Hoffmann-la Roche Ag

Jean-Claude Tardif

Marie-Pierre Dube

Eric Joseph Niesor

Ruchi Upmanyu

Christine Des Rosiers

Jocelyn Dupuis

Jean-Francois Lesgards

Pier-Luc Tardif

David Rhainds

Éric Rhéaume

David Busseuil

Gilles C&ocirc ;t&eacute;

Blandine Comte

Bertrand Bouchard

Caroline Asselin

Marie-Pierre Dubé

Eric J Niesor

Genotyping methods and compositions for selecting patients with cardiovascular disease who will benefit from treatment with HDL-raising or HDL mimicking agent, in particular with a CETP inhibitor/modulator.

Genetic markers for predicting responsiveness to therapy with HDL-raising or HDL mimicking agent

Cabinet pill dispenser

Disclosed are methods of treating Acute Respiratory Distress Syndrome using colchicine, e.g., by administering colchicine to a subject in need thereof.

Methods of treating acute respiratory distress syndrome using colchicine

The present invention provides a co-culture system and method for assessing cellular cholesterol (Choi) efflux and uptake in vitro. The co-culture system mimics in vivo Choi efflux and uptake in the context of mammalian physiology. The methods and systems provided can be used in some embodiments to evaluate the effect of a pharmacological agent on cellular Choi efflux and uptake or for diagnostic purposes.

Co-culture system and method for in vitro assessment of reverse cholesterol transport

The present invention provides genotyping methods and compositions for selecting patients with cardiovascular disease who will benefit from treatment with HDL-raising or HDL mimicking agent, in particular with a CETP inhibitor/modulator.

CETP inhibitors for therapeutic use

The invention relates to colchicine for use in a method of treating a patient after having a myocardial infarction (MI), the method including initiating the administration of colchicine at a daily low dose to the patient within about 3 days of the MI.

Early administration of low-dose colchicine after myocardial infarction

Dalcetrapib for therapeutic use

A method for treating valvular stenosis. The method involves the administration of a therapeutically effective amount of a reverse lipid (in particular cholesterol) transport agonist to a mammal. Most preferred is an Apolipoprotein A-1 mimetic peptide/phospholipid complex, the peptide of which is defined by the amino acid sequence of SEQ ID NO 1.

Method for the treatment of valvular disease

A method for characterizing oxidative stress. The method includes dosing a ratio of HNE-to-DHN-protein in blood; comparing the ratio of HNE-to-DHN-protein in blood to a predetermined interval of ratio values associated with a predetermined level of oxidative stress; and classifying the oxidative stress as having reached the predetermined level if the ratio of HNE-to-DHN-protein in blood is within the predetermined interval of ratio values.

Method for detecting a biomarker of oxidative stress in a biological sample

The present invention relates to methods for detecting a oxidative stress in a biological sample, methods of determining a cumulative record of oxidative injury, and methods of diagnosing diseases of aging, such as cardiovascular diseases, based on the presence or absence of a biomarker or a component thereof. The present invention also relates to a kit for detecting oxidative stress in a biological sample comprising a stabilizing reactant and an antibody. In some embodiments of the invention, the biomarker of oxidative stress is selected from an aldehyde-protein adduct and an aldehyde metabolite-protein adduct, and the proposed method further comprises measuring separately for the same protein biomarkers of oxydative stress formed with different amino acids of the protein.

Method for quantifying oxidative stress caused by different biological pathways

Probucol exerts a positive effect on vascular remodeling. By using probucol to promote vascular remodeling by the method of the invention, favorable results can be obtained in treating such diseases and conditions as restenosis following transluminal coronary angioplasty, intimal smooth muscle cell hyperplasia, vascular occlusion, or restenosis following transluminal angioplasty or atherectomy procedures performed on the coronary, iliac, femoral, renal or carotid arteries. This effect was determined based upon an IVUS substudy from the MVP trial. Beginning 30 days before PTCA, 317 patients were randomly assigned to receive either probucol, multivitamins, the combination of drugs, or placebo. Patients were then treated for six months after PTCA. 96 patients (111 segments) underwent IVUS examination immediately after angioplasty and at follow-up. The anatomic cross-section selected for serial analysis was the one at the angioplasty site with the smallest lumen area at follow-up. Quantitative analysis consisted in measurements of lumen area and the area within the external elastic membrane (EEM). Wall area was calculated as the difference between EEM and lumen areas. Results. In the placebo group, lumen area at follow-up decreased by &minus;1.21&plusmn;1.88 mm,, and wall and EEM areas increased by 1.50&plusmn;2.50 mm,and 0.29&plusmn;2.93 mm,. The change in lumen area correlated more strongly, however, with the change in EEM area (r&equals;0.53, p&equals;0.002) than with the change in wall area (r&equals;&minus;0.13, p&equals;0.49). Lumen loss was &minus;1.21&plusmn;1.88 mm,in the placebo group, &minus;0.83&plusmn;1.22 mm,for vitamins alone, &minus;0.25&plusmn;1.17 mm,for combined treatment and &minus;0.15&plusmn;1.70 mm,for probucol alone (p&equals;0.002 for probucol versus no probucol and p&equals;0.85 for vitamins versus no vitamins). The change in wall area was similar in all groups. EEM area increased at follow-up by 0.29&plusmn;2.93 mm,in the placebo group, 0.09&plusmn;2.33 mm,for vitamins only, 1.17&plusmn;1.61 mm,for combined treatment and 1.74&plusmn;1.80 mm,for probucol only (p&equals;0.006 for probucol versus no probucol).

Growing community of inventors

Montreal, Canada

Jean-Claude Tardif